"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that ...

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder ...

The U.S. FDA has approved Johnson & Johnson's INLEXZO (gemcitabine intravesical system) for adults with BCG-unresponsive ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...

The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...

The FDA has approved Inlexzo (gemcitabine intravesical system) for the treatment of adult patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS with or without papillary tumors.

Tumors with higher stromal content may have a TME in an immune-overstimulated state, which could be a factor in their worse prognosis, the researchers suggested. Based on its associations with PD-L1 ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limit | The ...

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...